Follow The Filings

ARWR Arrowhead Pharmaceuticals In

Health Care, filed as ARROWHEAD PHARMACEUTICALS IN (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 1

  • 1 Owner
  • $539K
  • 1 new 1 exit

In 2026 Q2 Polen Capital Management opened a position in Arrowhead Pharmaceuticals In, while Farallon Capital Management sold out.

Who owns ARWR

Sorted by value, long equity only, as of 2026 Q2.

History
Polen Capital Management <0.01% New <0.01% 6,612 $539K History
Farallon Capital Management exited 2026 Q2 Last 2026 Q1 0.01% Exit −0.01% 15,800 $991K History

1 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ARWR's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ARWR insider trades
  • None no insider bought on the open market
  • $2.7M sold by 3 insiders outside a trading plan
  • $10M sold by 8 insiders under 10b5-1 plans
  1. Michael S Perry Director
    Sale
    $1M 11,600 shares at $87.30 9.4% of stake
    Traded Aug 18 Filed Aug 20
    ↗
  2. Adeoye Y Olukotun Director
    Sale
    $174K 2,000 shares at $86.96 6% of stake
    Traded Aug 18 Filed Aug 20
    ↗
  3. Hongbo Lu Director
    Planned sale
    $228K 2,970 shares at $76.88 5.4% of stake
    Traded May 12 Filed May 14
    ↗
  4. James C Hamilton Chief Medical Officer
    Planned sale
    $750K 10,000 shares at $75.00 4.2% of stake
    Traded Apr 23 Filed Apr 24
    ↗
  5. James C Hamilton Chief Medical Officer
    Planned sale
    $642K 10,000 shares at $64.19 4% of stake
    Traded Mar 5 Filed Mar 9
    ↗
  6. Patrick O'Brien COO
    Planned sale
    $615K 9,755 shares at $63.03 2% of stake
    Traded Jan 5 Filed Jan 5
    ↗
  7. Mauro Ferrari Director
    Planned sale
    $527K 7,530 shares at $70.00 9.8% of stake
    Traded Dec 26, 2025 Filed Dec 30, 2025
    ↗
  8. Christopher Richard Anzalone CEO
    Planned sale
    $3.6M 51,726 shares at $69.13 1.3% of stake
    Traded Dec 29, 2025 Filed Dec 30, 2025
    ↗
  9. Victoria Vakiener Director
    Planned sale
    $679K 10,040 shares at $67.68 22% of stake
    Traded Dec 19, 2025 Filed Dec 23, 2025
    ↗
  10. William D. Waddill Director
    Planned sale
    $566K 8,367 shares at $67.65 13% of stake
    Traded Dec 19, 2025 Filed Dec 23, 2025
    ↗
  11. Christopher Richard Anzalone CEO
    Planned sale
    $1.8M 26,031 shares at $68.04 0.7% of stake
    Traded Dec 19–22 Filed Dec 23, 2025
    ↗
  12. Adeoye Y Olukotun Director
    Planned sale
    $677K 10,000 shares at $67.66 23% of stake
    Traded Dec 19, 2025 Filed Dec 23, 2025
    ↗
  13. Michael S Perry Director
    Sale
    $992K 16,250 shares at $61.03 12% of stake
    Traded Dec 5, 2025 Filed Dec 9, 2025
    ↗
  14. Mauro Ferrari Director
    Sale
    $493K 8,750 shares at $56.39 11% of stake
    Traded Nov 28, 2025 Filed Dec 1, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 35 sales to cover taxes, 12 stock grants, 10 gifts, and 2 option exercises.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.07,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,2.03,9.01 Filing Doc
424B5 Filing Doc
424B5 Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
424B5 Filing Doc
424B5 Filing Doc

Source: SEC EDGAR submissions, updated 15 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $240.74M $3.55M $829.45M
Net income -$205.28M -$599.49M -$1.63M
Net margin * -85.3% -16882.4% -0.2%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $419.52M $695.47M $950.64M
Total non-current assets * $346.03M $444.33M $434.66M
Total assets $0.766B $1.14B $1.39B
Total current liabilities $105.46M $103.17M $195.49M
Total non-current liabilities $372.93M $845.57M $686.39M
Total equity $271.34M $185.44M $466.05M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$153.89M -$462.85M $179.55M
Cash from investing -$96.16M -$420.07M -$129.29M
Cash from financing $253.05M $870.52M $74.01M
Net change in cash * $3.01M -$12.4M $124.26M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf